Femasys has initiated a post‑market surveillance clinical study for its CE‑marked FemBloc permanent birth control device in Europe, structured under EU MDR 2017/745 Annex XIV Part B and conducted to ISO 14155:2020 with approvals from multiple ethics committees. The program is designed to generate real‑world safety and performance evidence as the company advances commercialization following European approval in June 2025 and subsequent clearances in the UK and New Zealand.
The core event is a regulatory and market access step, not a new efficacy readout. Under MDR, post‑market clinical follow‑up is now expected for novel devices, particularly in categories where long‑term outcomes and failure modes can be consequential. FemBloc is an in‑office, non‑surgical approach intended to occlude both fallopian tubes via a polymer that degrades and induces scarring, offering an alternative to surgical sterilization. The PMS study will function as a prospective evidence engine to support the device’s clinical evaluation updates and periodic safety reporting, while supplying adoption and reimbursement dossiers with contemporary, region‑specific data.
Strategically, Femasys is aligning with MDR’s real‑world evidence bias to de‑risk European uptake of a permanent contraception device in a post‑Essure environment where clinicians and payers will demand transparent, longitudinal outcomes. The company is signaling an execution plan that marries regulatory compliance with commercialization: leverage PMCF data to drive physician confidence, training, and payer conversations while extending reach through country‑level partnerships. The approach also hedges the timing of the ongoing U.S. FINALE pivotal trial by building a European evidence base that can mature independently and potentially backstop broader global positioning.
Operationally, the study affects stakeholders across the ecosystem. OB/GYN sites will need to operationalize ISO‑conformant processes in office settings, including screening, procedure standardization, and structured follow‑up to confirm tubal occlusion—likely via the company’s ultrasound‑based FemChec assessment—and to monitor pregnancy rates, ectopic events, pain, device‑related complications, and any need for re‑intervention. CROs with EU MDR PMCF infrastructure stand to benefit from multi‑country governance, data capture, and monitoring demands unique to device RWE. Notified Bodies and competent authorities will scrutinize the granularity and completeness of the dataset, including adherence to follow‑up windows and subgroup performance. Payers will look for comparative signals versus laparoscopic sterilization on effectiveness, adverse events, procedure time, and total cost of care, as well as evidence that office‑based delivery translates into measurable system savings without compromising outcomes.
What to watch next is cadence and quality: enrollment and retention over 12–24 months, interim PMCF outputs on confirmed occlusion and on‑study pregnancies, and whether adverse event patterns remain manageable as use scales beyond early adopters. Country‑specific reimbursement and coding decisions, particularly in markets where office‑based procedures have distinct tariffs, will be pivotal to uptake. The company’s ability to stand up training and proctoring networks will influence variability across sites and geographies. Any safety signal or higher‑than‑expected failure rate could trigger heightened Notified Body scrutiny and slow commercial momentum; conversely, consistent real‑world performance could accelerate guideline consideration and payer alignment. The interplay with the U.S. FINALE trial is also material: congruent safety and effectiveness profiles across PMCF and pivotal cohorts would strengthen the overall narrative, while divergence would complicate both regulatory and market strategies.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
